AKT1 deficiency led to the inhibition of AKT/mTOR/S6K signaling pathway in hepatocytes, which was crucial for the development of hepatic steatosis and provided a new scheme for the development of NAFLD therapy (20). This evidence concerns the gene RPS6KB1 and metabolic dysfunction-associated steatotic liver disease.